Standard fractionated radiotherapy for the treatment of cancer consists of daily irradiation of 2-Gy X-rays, 5 days a week for 5-8 weeks. To understand the characteristics of radioresistant cancer cells and to develop more effective radiotherapy, we established a series of novel, clinically relevant radioresistant (CRR) cells that continue to proliferate with 2-Gy X-ray exposure every 24 h for more than 30 days in vitro. We studied three human and one murine cell line, and their CRR derivatives. Guanine nucleotide-binding protein 1 (GBP1) gene expression was higher in all CRR cells than their corresponding parental cells. GBP1 knockdown by siRNA cancelled radioresistance of CRR cells in vitro and in xenotransplanted tumor tissues in nude mice. The clinical relevance of GBP1 was immunohistochemically assessed in 45 cases of head and neck cancer tissues. Patients with GBP1-positive cancer tended to show poorer response to radiotherapy. We recently reported that low dose long-term fractionated radiation concentrates cancer stem cells (CSCs). Immunofluorescence staining of GBP1 was stronger in CRR cells than in corresponding parental cells. The frequency of Oct4-positive CSCs was higher in CRR cells than in parental cells, however, was not as common as GBP1-positive cells. GBP1-positive cells were radioresistant, but radioresistant cells were not necessarily CSCs. We concluded that GBP1 overexpression is necessary for the radioresistant phenotype in CRR cells, and that targeting GBP1-positive cancer cells is a more efficient method in conquering cancer than targeting CSCs. R adiotherapy is one of the major therapeutic modalities for eradicating malignant tumors. The existence of radioresistant cells remains one of the major obstacles in radiotherapy and chemoradiotherapy. Ordinary radiotherapy for cancers is composed of fractionated radiation (FR), with approximately 2 Gy of X-ray irradiation once a day, 5 days a week, over a 5-8-week period. (1) In order to develop more effective tumor radiotherapies, we established three human and one murine clinically relevant radioresistant (CRR) cell lines independently. These cells continue to proliferate under exposure to 2 Gy ⁄ day for more than 30 days in vitro. (2, 3) The total dose to these CRR cells over the whole process added up to more than 1500 Gy. We carried out cDNA microarray analyses of differential gene expression in association with the CRR phenotype. We found that the Guanine nucleotide-binding protein 1 (GBP1) gene was overexpressed in all of the CRR cells examined.
GBP1 is a member of the large GTPase family. (4) The human large GTPase family consists of seven members, encoded by a gene cluster located on chromosome 1.
(5) GBP1 is one of the genes most strongly induced by interferons. (6) GBP1 is highly expressed in endothelial cells, where it inhibits the proliferation and invasion of endothelial cells in response to c-interferon and is activated by inflammatory cytokines in vitro and in vivo. (7) (8) (9) Downregulation of GBP1 by siRNA resulted in higher levels of hepatitis C virus replication in a human hepatoma cell line, Huh-7. (10) In addition to the GTPase activity and its involvement in viral infections, GBP1 overexpression also contributes to cell survival by inhibiting apoptosis in human umbilical vein endothelial cells after growth factor and serum depletion. (11) Ovarian cancer cases with GBP1 protein overexpression are resistant to paclitaxel, leading to poor prognoses. (12) GBP1 overexpression is directly associated with moderate levels of paclitaxel resistance in ovarian cancer cell lines. (13) Higher GBP1 levels are associated with higher pathological stages, positive perineural invasion, and poorer prognosis of patients with oral squamous cell carcinoma. (14) In this study we found that GBP1 is necessary but not sufficient for cellular radiore-sistance in vitro. We carried out immunohistochemical studies on clinicopathological specimens from head and neck cancers (HNC) to confirm the relevance of GBP1 in cancer treatment. This study revealed that GBP1 is one of the key molecules contributing to radioresistance.
Materials and Methods
Cell culture and drugs. Human cancer cell lines SAS, HepG2, and KB and a mouse breast cancer cell line, MM102, were obtained from the Cell Resource Center for Biomedical Research (IDAC, Tohoku University, Sendai, Japan). We established CRR cell lines SAS-R1, HepG2-8960-R, and KB-R by exposing these parental cells to FR of X-rays for more than 5 years. (3) For the maintenance of the CRR phenotype, FR at 2 Gy was carried out every 24 h. All cells used in this study were maintained in RPMI-1640 medium (Nacalai Tesque, Kyoto, Japan) and supplemented with 5% FBS (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere at 37°C in air with 5% CO 2 . Acute exposure experiments were carried out with cells in the exponential growth phase, 24 h after the last maintenance irradiation. We introduced pIRES GBP1 expression vectors (13) into CRR cells by Lipofectamine 2000 (Invitrogen) and selected colonies resistant to 100 lg ⁄ mL G418 (Geneticin, Grand Island, NY, USA).
Irradiation. X-ray irradiation was carried out in a 150-KVp X-ray generator (MBR-1520R; Hitachi, Tokyo, Japan) with a total filtration of 0.5 mm aluminum plus 0.1 mm copper filter, at a dose rate of 1.0 Gy ⁄ min.
Cell survival assay after irradiation. Cell survival was determined by the modified high density survival (MHDS) assay. (15) Microarray analysis. Genome-wide expression arrays (Illumina, San Diego, CA, USA) were used for the analysis of SAS (human WG6, version 3, 48 803 genes) and HepG2 (human WG6, version 1, 47 296 genes). Data were analyzed by TransGenic (Kumamoto, Japan). For MM102, a 3D-Gene mouse Oligo chip 24k (23 522 genes; Toray Industries, Tokyo, Japan) was used and the data were analyzed by Toray Industries using GeneSpring GX10 (Agilent Technologies, Santa Clara, CA, USA). HepG2 versus HepG2 cancer stem cell (CSC) analysis was carried out by MOGERA-Array self (Tohoku Chemical, Iwate, Japan).
Antibodies. The primary antibodies used were as follows: anti-b-actin (A5316; Sigma, St. Louis, MO, USA), anti-GBP1 (15303-1-AP; Proteintech Group, Chicago, IL, USA), purified anti-H2AX-phosphorylated (cH2AX) (Ser139; BioLegend, San Diego, CA, USA), anti-Oct4 antibody 7E7 (ab105931; Abcam, Cambridge, MA, USA), CD34 (ab8158, Abcam), anti-GBP2 N1C1 (GTX114426; GeneTex, Irvine, CA, USA), anti-GBP3 C-term (AP18451b; Abgent, San Diego, CA, USA), anti-GBP5 N1N3 (GTX106994; GeneTex), anti-TAP1 53H8 (GTX10356; GeneTex), and interleukin (IL)-15 (sc-1296; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The secondary antibodies used were as follows: goat anti-rabbit IgG (H1202; Nichirei Bioscience, Tokyo, Japan), mouse anti-rat IgG (H1104; Nichirei Bioscience), Alexa Fluor 488 goat anti-mouse IgG (A11001; Invitrogen), and Alexa Fluor 594 goat anti-rabbit IgG (A11012, Invitrogen).
Western blot analysis. Western blot of whole cell lysates was carried out as previously described. (16) Reverse transcription-PCR. Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was synthesized by RT using SuperScriptIII Reverse Transcriptase (Invitrogen). Reverse transcription-PCR of GBP1 was carried out using the primer pair 5 0 -CTGCACAGGCTTCAGCAAAA-3 0 and 5 0 -AAGGCTCTGGTCTTTAGCTT-3 0 . (13) Reverse transcription-PCR of ISG20 was carried out using the primer set 5 0 -ATCTCTGAGGGTCCCCAAG-3 0 and 5 0 -TTCAGTCTG ACACAGCCAGG-3 0 . (17) The RT-PCR was carried out using TB SYBR gPCR Mix (Toyobo, Osaka, Japan). The PCR conditions were: 95°C for 1 min, followed by 60 cycles of 95°C for 15 s, and 60°C for 30 s using the Thermal Cycler Dice Real Time System (Takara, Shiga, Japan).
RNA interference. Lipofectamine 2000 was used for transfection. GBP1 siRNA (Hs_GBP1_8 and Hs_GBP1_9) and AllStars Negative Control siRNA were purchased from Qiagen.
Apoptosis assay. Apoptotic cells were quantified using an annexin V-FITC apoptosis detection kit (BioVision, Mountain View, CA, USA). Cells (5 9 10 5 ) were collected 48 h after irradiation and were analyzed by a FACScan (Cytomics FC500; Becton Dickinson, Mountain View, CA, USA).
Immunofluorescence staining of culture cells. Immunofluorescence staining was carried out as previously described. (18) Images were randomly captured in a fluorescence microscope (BZ-8000; Keyence, Osaka, Japan). We scored cH2AX foci and Oct4-positive cells by counting 50 cells in total.
Animal experiments. This study was approved by Regulations for Animal Experiments and Related Activities, Tohoku University, and carried out as described previously. (16) Atelo Gene (Koken, Tokyo, Japan) was used to deliver siRNA into animal tissues according to the manufacturer's protocol.
Immunohistochemistry. Tumor tissues were fixed in 10% formalin and immunohistochemical staining was carried out as described previously. (19) In situ hybridization. GBP1 (NM_002053) gene expression in tumor tissues was visualized using RNAscope and the HybEZ system according to the manufacturer's protocol (Advanced Cell Diagnostics, Hayward, CA, USA).
Demographic analysis. This study was approved by the committees of medical ethics, Shinshu University School of Medicine (No.354; Matsumoto, Japan) and Tohoku University, Graduate School of Medicine (No. 2011-42, 2013-1-1). We carried out immunohistochemical studies on biopsy specimens from HNC before treatment at Shinshu University Hospital and Tohoku University Hospital. The correlation between relative protein expression and clinicopathological data was analyzed using the Behrens-Fisher test.
Statistical analysis. Experiments in vitro were carried out in triplicate and were statistically analyzed using Student's t-test.
Results
Identification of GBP1 overexpression by cDNA array analysis. We carried out a cDNA array analysis to identify genes whose expression was changed 12 h after exposure to 2-Gy X-rays (2-Gy-12 h). We compared the expression profile of CRR cells and their corresponding parental cells. In order to avoid the influence of the maintenance irradiation other than radioresistance, we also analyzed SAS-R1-NOIR cells, which were cultured CRR cells without maintenance exposure. We confirmed that NOIR cells were also radioresistant, as determined by the MHDS assay (Fig. S1a) . We first compared SAS, SAS 2-Gy-12 h, SAS-R1 2-Gy-12 h, and SAS-R1 NOIR (Fig. 1a) . We found 1636 genes whose expression in CRR cells was more than twice that in corresponding parental cells, regardless of irradiation. We also carried out the same analysis among the MM102 series and found 206 genes that were overexpressed in CRR cells compared with parental cells, regard-less of irradiation. Compared with the corresponding parental cells, 23 genes were commonly overexpressed in SAS-R1 and MM102-R cells. We finally confirmed that two genes, GBP1 and ISG20, were commonly overexpressed in CRR cells of the HepG2 series (Fig. 1a,b) .
Verification of GBP1 overexpression by RT-PCR. Compared with their corresponding parental cells, GBP1 expression was commonly higher (Fig. 1c) in HepG2-8960-R as well as SAS-R1 cells, whereas ISG20 expression was not.
Verification of GBP1 protein overexpression by Western blotting. All of the CRR cells examined showed higher GBP1 expression than their corresponding parental cells and NOIR cells (Fig. 1d ). HepG2 and KB showed only a trace amount of the GBP1 protein, irrespective of irradiation. GBP1 protein expression was higher in NOIR cells than in parental cells. GBP1 expression in SAS-R1 NOIR and KB NOIR tended to be higher after 2-Gy irradiation than without irradiation. SAS, the most radioresistant line, showed the highest expression of GBP1 protein among the parental cells. These results confirmed that GBP1 protein expression was correlated to radioresistance. We picked up proteins directly connected with GBP1 on the network such as GBP2, GBP3, GBP5, TAP1 and IL-15 in reference to COXPRESdb (http://coxpresdb.jp/). No associations were observed among their protein levels (Fig. S2d) .
Decreased radioresistance by GBP1 gene knockdown. In order to determine whether GBP1 was involved in radioresistance or not, the MHDS assay was carried out after cells were transfected with two types of GBP1 siRNA, GBP1_8 and GBP1_9 (Fig. S2a) . During this period of experiments, GBP1 gene expression was suppressed (Fig. S2b) . In all of the CRR cells examined, GBP1 knockdown cancelled radioresistance to the levels of their parental cells (Figs 2 and S1b). Furthermore, GBP1 knockdown increased radiosensitivity in parental cells. These indicate that GBP1 is one of the key molecules commonly involved in coping with radiation exposure, both in CRR and parental cells. Because suppression with GBP1_8 was stronger than with GBP1_9, further experiments were carried out using GBP1_8.
Association of GBP1 overexpression and radioresistance. To determine whether GBP1 directly participates in the establishment of the radioresistant phenotype, we transfected parental cells with a GBP1 expression vector. We confirmed GBP1 protein overexpression in all transfected parental cells (Fig. S2c) . The expression level was even higher in transfected cells of SAS and KB compared to their CRR cells. In all the parental cells, GBP1 transfection did not show significant change in radioresistance (Fig. 2c) .
Relationship between suppressing GBP1 and cell death. As GBP1 knockdown increased radiosensitivity, we examined the association of GBP1 expression and radiation-induced cell death by FACS. The frequency of apoptosis induced by 10-Gy X-rays was significantly higher in CRR cells with siGBP1 than with scrambled RNA in all cell lines examined (Fig. 3a) . DNA double-strand breaks (DSBs) induced by 2-Gy X-rays were determined by cH2AX staining. GBP1 knockdown increased DNA DSBs by irradiation (Figs 3b,c and S3a,b) .
Relationship between suppression of GBP1 and CSCs. We isolated surviving CSCs by exposure to long-term 0.5-Gy FR for 82 days from HepG2 cells. (20) Microarray analysis showed that the mRNA level of GBP1 was significantly higher in HepG2 CSCs than in HepG2 cells (Fig. 4a) . Additionally, the protein level of GBP1 was higher in HepG2 cells after FR than in non-radiated HepG2 cells (Fig. 4b) . Therefore, we examined the relationship between Oct4 expression and long-term FR. The frequency of Oct4-positive cells was higher in cells exposed to 0.5-Gy FR every 12 h for 30 days than in parental cells and was the highest in CRR cells (Fig. 4c) . We examined whether Oct4-positive CSCs coincided with GBP1-positive cells by immunostaining. Even in CRRs, Oct4-positive cells constituted less than 8% of total cells (Fig. 4d) . In contrast, GBP1 was positive in all CRR cells.
GBP1 immunohistochemistry in xenotransplanted tumor
tissues. SAS-R1 tumors transplanted into nude mice are also resistant to FR. (16) We found overexpression of both the GBP1 protein and mRNA in SAS-R1 tumors and KB-R tumors, compared with their parental cell-derived tumors (Fig. 5a) . In order to determine the association of GBP1 with tumor radioresistance, we suppressed GBP1 by AteloGenedelivered siRNA into animal tissues (Fig. S4) and irradiated with FR of 2-Gy ⁄ day for 5 days (Fig. 5b) . GBP1 suppression alone did not affect the growth or microvessel density (MVD) of SAS and SAS-R1 tumors. However, SAS-R1 tumors shrank if combined with irradiation. In parental tumors, irradiation diminished the growth irrespective of GBP1 suppression.
GBP1 immunohistochemistry of clinical samples. Immunohistochemical study of GBP1 was possible in 45 cases of HNC before treatment. Clinicopathological features of cases are shown in Table 1 . We defined a case GBP1-positive if the nucleus and cytoplasm of more than 5% of tumor cells were positive for GBP1 (Fig. 5c) . Only one GBP1-positive case and seven GBP1-negative cases out of a total of 45 cases were without recurrence or metastasis 5 years after chemoradiation treatment (Table 1a) . GBP1-positive cases were significantly more resistant to chemoradiotherapy than GBP1-negative cases (P < 0.05, Behrens-Fisher test).
Discussion
Radiotherapy with FR is one of the major modalities for cancer treatment. Although tumors receive a large total dose, they sometimes recur and demonstrate radioresistance. In this study, we looked for genes whose overexpression was responsible for the radioresistant phenotype of CRR cells. In microarray analyses, we found two such candidate genes in common with human and murine CRR cells. We finally picked up only one gene, GBP1, whose overexpression in CRR cells was confirmed by RT-PCR. The translational level of GBP1 was closely correlated to the transcriptional step (Fig. 1d) . The expression levels of GBP1 protein were not different between parental cells with and without 2-Gy irradiation. All the CRR and NOIR cells examined showed GBP1 overexpression, compared with their corresponding parental cells. This indicates that GBP1 protein overexpression is associated with radioresistance and is mainly regulated at the transcriptional step. Knockdown of GBP1 cancelled radioresistance to the level of parental cells in all the CRR cells including HepG2 and KB with naturally low GBP1 expression (Figs 2a,b and S1b,c). This radiosensitization by GBP1 gene knockdown was also observed in transplanted SAS-R1 tumors (Fig. 5b) . However, parental cells with GBP1 transfection did not demonstrate significant changes of radioresistance even in SAS and KB cells with much more GBP1 protein than their corresponding CRR cells (Figs 2c and S2c). These results indicate that GBP1 is essential to cope with radiation, but is not enough to shift the cell into CRR. Only GBP1 knockdown in CRR cells did not enhance apoptosis but induced apoptosis through increased radiation-induced DNA DSBs in an additive manner (Figs 3 and S3a,b). Sublethal damage that is substantiated by FR is suggested to be restored by homologous recombination repair (HRR) of DSBs. (21) Therefore, prolongation of cH2AX foci in CRR cells by GBP1 knockdown is suggested to represent the deficiency in HRR of radiation-induced DSBs. (22) A member of GTPases, RECQ5 ⁄ QE DNA helicase is activated by GTP binding. (23) These suggest that GBP1 is involved in radioresistance through HRR of DSBs. However, the failure of enhancing radioresistance by GBP1 overexpression in parental cells indicated that HRR requires multiple molecules other than GBP1.
Overexpression of GBP1 activates class III b-tubulin and ultimately leads to paclitaxel resistance in ovarian cancer cells. (12, 13) Nevertheless, GBP1 protein expression was not significantly changed by treatment with cisplatin or 5-fluorouracil (Fig. S5) . Extrapolating from these findings, GBP1 plays a role in radioresistance but not in chemoresistance.
The GBP1 gene is located at tight junctions of intestinal epithelial cells of inflammatory bowel disease and its knockdown enhances apoptosis. (24) We previously reported that inhibition of the AKT ⁄ cyclin D1 pathway suppresses acquired radioresistance through increased apoptosis. We need to study the relationship between GBP1 and the AKT ⁄ cyclin D1 pathway. (25) In this study, GBP1 knockdown enhanced radiationinduced early apoptosis in CRR cells through the delay of DSB repair. We also reported that hyperinduction of autophagy is involved in radiation-induced cell death later than 5 days after radiation. (3) Combined induction of apoptosis and autophagy hyperinduction would be effective to conquer CRR cancers.
Recently, we reported that exposure to FR with 0.5-Gy X-rays every 12 h for 82 days enriched CSCs, owing to their radioresistance. (20) Microarray analysis showed that GBP1 gene expression increased along with the accumulation of total dose (Fig. 4b) . Immunofluorescence of GBP1 staining was stronger in all CRR cells than their corresponding parental cells but not all CRR cells were Oct4-positive (Fig. 4c) . These results indicate that radiotherapy, in combination with targeting GBP1-positive cancer cells, is more efficient in impeding cancer than targeting CSCs.
The growth rate of transplanted murine mammary tumors transfected with GBP1 is slower accompanied with lower MVD compared with those without transfection. (26) Overexpression of GBP1 in human endothelial cells decreases apoptosis but inhibits cell proliferation. (11) Patients with colorectal cancer with GBP1-positive stromal cells showed better prognosis than those with GBP1-negative cases. (27) In this study, CRR tumors revealed higher MVD compared to their parental cell tumors, suggesting that GBP1 of cancer cells is not involved in tumor vasculature. It is interesting to study the expression and role of GBP1 in normal cells, especially in endothelial cells after FR.
Reports of the association of GBP1 with chemotherapeutic taxanes are conflicting; GBP1 is a marker of paclitaxel-resistant cancer cells (12) and a marker of docetaxel-sensitive cancer cells. (28) In this study, GBP1-positive HNC was clinically resistant to radiotherapy but was not associated with resistance to cisplatin and 5-fluorouracil. These results suggest that GBP1 plays a role in radioresistance, but not in chemoresistance, and may be a useful marker for screening of specifically radioresistant tumors before treatment.
The precise mechanism of GTP hydrolyzing activity of GBP1 and its role in signal transduction remains unknown. (29, 30) Our study is the first to reveal another aspect of GBP1, namely radioresistance. Our results suggest that the suppression of GBP1 transcription may overcome tumor radioresistance and that GBP1 could be used for screening radioresistant malignant tumors.
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